非酒精性脂肪性肝病治疗进展

施军平; 荀运浩

doi:10.3969/j.issn.1001-5256.2013.12.004

非酒精性脂肪性肝病治疗进展

DOI: 10.3969/j.issn.1001-5256.2013.12.004

1. 杭州师范大学附属医院
2. 杭州市西溪医院

基金项目:

浙江省自然科学基金项目(Y2091159,Y2091200)；浙江省医药卫生科技计划项目(2011KYA132)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2986
- HTML全文浏览量: 8
- PDF下载量: 694
- 被引次数: 0
出版历程
- 收稿日期: 2013-08-08
- 出版日期: 2013-12-20

Progress in treatment of nonalcoholic fatty liver disease

The Affiliated Hospital of Hangzhou Normal University

Research funding:

摘要

摘要: 非酒精性脂肪性肝病（NAFLD）的发病随肥胖流行迅速增加,但特效治疗方法缺乏。首先评述了生活方式修正不同实施策略的可能临床获益、提高干预效果的方法和存在问题;其次简单介绍了减肥手术的适应证和主要研究方向;最后对维生素E、法尼酸X受体激动剂、肠道微生态制剂、多不饱和脂肪酸、胰高糖素样肽-1受体激动剂、己酮可可碱等几类有前景的药物进行了较全面的介绍。目前获得的这些临床证据和来自基础领域的有关研究进展表明:生活方式修正是所有NAFLD患者治疗的基础,但实施方案须要改进以提高干预效果;减肥手术是无禁忌症病态肥胖NAFLD患者的有效治疗选择之一;药物治疗则应选择性用于确诊的非酒精性脂肪性肝炎人群。
- 脂肪肝
Abstract: The incidence of nonalcoholic fatty liver disease ( NAFLD) increases with the prevalence of obesity, but specific treatment for this disease is lacking. First, the possible clinical benefits from different strategies of lifestyle modification, as well as the methods for improving intervention effect and existing problems, are reviewed. Second, the indications for bariatric surgery and the main research directions are briefly presented. Finally, several promising drugs including vitamin E, farnesoid X receptor agonist, intestinal probiotics, polyunsaturated fatty acids, glucagon-like peptide-1 receptor agonist, and pentoxifylline are elaborated on. The currently acquired clinical evidence and progress in basic research suggest that lifestyle modification is the basis for treatment in all patients with NAFLD, but better schemes are needed to improve the intervention effect; bariatric surgery is one of the effective therapies for NAFLD patients with morbid obesity who have no relevant contraindications; drug treatment should be selectively applied to the population with a confirmed diagnosis of NAFLD.
- fatty liver

HTML全文

参考文献(31)

[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J].Hepatology, 2012, 55 (6) :2005-2023.

[2]MUSSO G, CASSADER M, ROSINA F, et al.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) :a systematic review and meta-analysis of randomised trials[J].Diabetologia, 2012, 55 (4) :885-904.

[3]WONG VW, CHAN RS, WONG GL, et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:A randomized controlled trial[J].J Hepatol, 2013, 59 (3) :536-542.

[4]CENTIS E, MOSCATIELLO S, BUGIANESI E, et al.Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease[J].J Hepatol, 2013, 58 (4) :771-777.

[5]KEATING SE, HACKETT DA, GEORGE J, et al.Exercise and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 57 (1) :157-166.

[6]SULLIVAN S, KIRK EP, MITTENDORFER B, et al.Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (6) :1738-1745.

[7]NASCIMBENI F, PAIS R, BELLENTANI S, et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol, 2013, 59 (4) :859-871.

[8]STEPHEN S, BARANOVA A, YOUNOSSI ZM.Nonalcoholic fatty liver disease and bariatric surgery[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (2) :163-171.

[9]VERDAM FJ, SCHOUTEN R, GREVE JW, et al.An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery[J].J Obes, 2012, 2012:597871.

[10]BELL LN, WANG J, MURALIDHARAN S, et al.Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis:a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study[J].Hepatology, 2012, 56 (4) :1311-1318.

[11]HOOFNAGLE JH, van NATTA ML, KLEINER DE, et al.Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2013, 38 (2) :134-143.

[12]D'ADAMO E, MARCOVECCHIO ML, GIANNINI C, et al.Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E[J].Free Radic Res, 2013, 47 (3) :146-153.

[13]MUDALIAR S, HENRY RR, SANYAL AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type2 diabetes and nonalcoholic fatty liver disease[J].Gastroenterology, 2013, 145 (3) :574-582.e1.

[14]ADORINI L, PRUZANSKI M, SHAPIRO D.Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis[J].Drug Discov Today, 2012, 17 (17-18) :988-997.

[15]KRAJMALNIK-BROWN R, ILHAN ZE, KANG DW, et al.Effects of gut microbes on nutrient absorption and energy regulation[J].Nutr Clin Pract, 2012, 27 (2) :201-214.

[16]PARNELL JA, RAMAN M, RIOUX KP, et al.The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance[J].Liver Int, 2012, 32 (5) :701-711.

[17]ENDO H, NIIOKA M, KOBAYASHI N, et al.Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats:new insight into the probiotics for the gut-liver axis[J].PLoS One, 2013, 8 (5) :e63388.

[18]ST-JULES DE, WATTERS CA, BRUNT EM, et al.Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2013, Jun 30.[Epub ahead of print]

[19]TANAKA N, SANO K, HORIUCHI A, et al.Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2008, 42 (4) :413-418.

[20]CAPANNI M, CALELLA F, BIAGINI MR, et al.Prolonged n-3polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a pilot study[J].Aliment Pharmacol Ther, 2006, 23 (8) :1143-1151.

[21]PARKER HM, JOHNSON NA, BURDON CA, et al.Omega-3supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 56 (4) :944-951.

[22]SCORLETTI E, BYRNE CD.Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease[J].Annu Rev Nutr, 2013, 33:231-248.

[23]LPEZ-VICARIO C, GONZLEZ-PERIZ A, RIUS B, et al.Molecular interplay between Delta5/Delta6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis[J].Gut, 2013, Mar 14.[Epub ahead of print]

[24]SAMSON SL, BAJAJ M.Potential of incretin-based therapies for non-alcoholic fatty liver disease[J].J Diabetes Complications, 2013, 27 (4) :401-406.

[25]ZEIN CO, YERIAN LM, GOGATE P, et al.Pentoxifylline improves nonalcoholic steatohepatitis:a randomized placebo-controlled trial[J].Hepatology, 2011, 54 (5) :1610-1619.

[26]SHARGORODSKY M, OMELCHENKO E, MATAS Z, et al.Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis:effects beyond glucose lowering?[J].Cardiovasc Diabetol, 2012, 11:61.

[27]CHEN HP, SHIEH JJ, CHANG CC, et al.Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner:population-based and in vitro studies[J].Gut, 2013, 62 (4) :606-615.

[28]NSEIR W, MOGRABI J, GHALI M.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis:human studies[J].Dig Dis Sci, 2012, 57 (7) :1773-1781.

[29]HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al.Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:a randomized controlled pilot study[J].Hepat Mon, 2012, 12 (8) :e6099.

[30]LOGUERCIO C, ANDREONE P, BRISC C, et al.Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease:a randomized controlled trial[J].Free Radic Biol Med, 2012, 52 (9) :1658-1665.

[31]SHI KQ, FAN YC, LIU WY, et al.Traditional Chinese medicines benefit to nonalcoholic fatty liver disease:a systematic review and meta-analysis[J].Mol Biol Rep, 2012, 39 (10) :9715-9722.

施引文献

资源附件(0)

访问统计